ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 2242 • ACR Convergence 2025

    Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis

    Ivanna Romankevych1, Donna Do1, Alyssa Sproles2, Lexi Auld1, Taskin Sabit1, Richard Chhaing1, Joy Baker1, John Brewington3, Christopher Towe4, Alexiei GROM5 and Grant Schulert6, 1Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Division of Pulmonary Medicine; University of Cincinnati, Cincinnati, OH, 4Cincinnati Children’s Hospital Medical Center, Division of Pulmonary medicine; University of Cincinnati, Cincinnati, OH, 5Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: The lung disease associated with systemic JIA (SJIA-LD) remains poorly understood. Measurement of cytokine levels in bronchoalveolar lavage fluid (BALF) may offer insights into…
  • Abstract Number: 1652 • ACR Convergence 2025

    The Hidden Impact of Hyperuricemia on Immune Cell Dysfunction

    Isabella Yi, Henry Ping and Qian Wang, iLab Research Institute, Mountain View, CA

    Background/Purpose: Background: Hyperuricemia, characterized by elevated serum uric acid levels, is often asymptomatic yet poses serious health risks. This study investigates how soluble monosodium urate…
  • Abstract Number: 0939 • ACR Convergence 2025

    Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus

    Chengfeng Xue1, Jingjing Wang1, Mengwen Huang1, Ting Liu1, Panpan Wang1, Donghai Chen2, Xue Wang1, Yawei Xu1, Yajun Gong1, Jun Yang1, Xiaoshan Yu1, Ke Wang1, Yuqing Zhu1, Kaixuan Zhu1, Tianqi Tang1, Wantong Qi1, Yaqiong Pei1, Qiyao Zhang1, Fugang Li2, Qingyang Gu1 and Xiangnan Qiang1, 1WuXi AppTec, Shanghai, China (People's Republic), 2WuXi ApptTec, Shanghai, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and immunological manifestations. Bruton’s tyrosine kinase (BTK) is a crucial intracellular kinase in…
  • Abstract Number: 0281 • ACR Convergence 2025

    Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies

    Anja Srpcic1, Manca Ogric1, Sasa Cucnik1, Sergej Pirkmajer2, Katja Lakota1 and Katja Perdan Pirkmajer1, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
  • Abstract Number: 2092 • ACR Convergence 2025

    Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study

    Jasmine Kimber1, Carolina Alvarez2, Virginia Kraus3, Janet Huebner3, Liubov Arbeeva4, Todd Schwartz5, Yvonne Golightly6, Richard Loeser7 and Amanda Nelson1, 1University of North Carolina at Chapel HIll, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Miami, FL, 3Duke University, Durham, NC, 4University of North Carolina, Chapel Hill, Carrboro, NC, 5University of North Carolina-Chapel Hill, Chapel Hill, NC, 6University of Nebraska Medical Center, Omaha, NE, 7University of North Carolina, Chapel Hill, NC

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability worldwide, characterized by progressive joint degeneration, chronic pain and functional impairment (PMID: 24024017). While imaging modalities…
  • Abstract Number: 1651 • ACR Convergence 2025

    Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations

    Mary Maclean1, Sabrina Helmold Hait2, Cindy Phung3, Deborah Stone4, Sophie georgin-Lavialle5, Scott Canna6, Carl Esperanzate7, Amanda Ombrello8, Daniel Kastner9, Ivona Aksentijevich10 and Massimo Gadina11, 1NIH-NIAMS, Rockville, MD, 2NIAMS/NIH, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, 4NIH, Bethesda, MD, 5Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 6Children's Hospital of Philadelphia, Philadelphia, PA, 7National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, 8National Institutes of Health, Rockville, MD, 9National Human Genome Research Institute, Bethesda, MD, 10100, Bethesda, MD, 11National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD

    Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease associated with biallelic pathogenic variants in the MEFV gene encoding the myeloid-restricted inflammasome sensor pyrin. The…
  • Abstract Number: 0931 • ACR Convergence 2025

    Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage

    Salvador Campos1, Sergio Aguilera2, Juan Gutiérrez1, Isabel Castro3, Patricia Carvajal3, Lorena Carvajal1, Sergio González4, Claudio Molina5, María-Julieta González6 and María-José Barrera5, 1Universidad San Sebastián, Santiago, Region Metropolitana, Chile, 2Clinica Indisa, Santiago, Region Metropolitana, Chile, 3Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, 4Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, 5Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, 6ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile

    Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
  • Abstract Number: 0141 • ACR Convergence 2025

    Cytokine profiles in antiphospholipid syndrome

    Xiangjun Liu1, Yuzhou Gan2, Chun Li3, Jianping Guo4, lei zhu5 and yuan jia3, 1Peking University, Beijing, Beijing, China, 2University of Michigan, Ann Arbor, MI, 3Peking University People's Hospital, Beijing, China (People's Republic), 4Peking University People's Hospital, Beijing, Beijing, China, 5Affiliated Nantong Rehabilitation Hospital of Nantong University, Nantong, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…
  • Abstract Number: 2035 • ACR Convergence 2025

    Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease

    Joshua Friedman1, JD Lu2, Bing Wang2, Kinjal Hew2, Preeyam Patel2, Michael Kennedy2, Mark Rose2, Curtis Sheldon2, Rachel McLean2, Emily Svejnoha2, MiRa Huyghe1, Brian Connolly2 and Deanna Nguyen2, 1Spyre Therapeutics, Waltham, MA, 2Spyre Therapeutics, Waltham

    Background/Purpose: TL1A is an inflammatory cytokine and a member of the TNF superfamily. Target cells that express DR3 and respond to TL1A include T cells,…
  • Abstract Number: 1622 • ACR Convergence 2025

    Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib

    jing luo1 and Lan He2, 1the first affiliated hospital of xi'an jiaotong university, xi'an, China (People's Republic), 2The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic)

    Background/Purpose: To investigate the efficacy of tofacitinib (TOF) in patients with active TAK, explore the effect on CD4+ regulatory T cells (Tregs) homeostasis and relationship…
  • Abstract Number: 0909 • ACR Convergence 2025

    Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.

    Marcus Hines1, Timothy Borbet2 and Sergei Koralov2, 1New York University Grossman School of Medicine, New York, NY, 2NYU Langone Medical Center, New York

    Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
  • Abstract Number: 0109 • ACR Convergence 2025

    Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation

    Juan Liang1 and Yinlian Zhang2, 1Gempharmatech, Nanjing, Jiangsu, China, 2GemPharmatech, Nanjing, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
  • Abstract Number: 2010 • ACR Convergence 2025

    Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli

    Tony Merriman1, Christopher Hall2, Annie Chien2, Richard Reynolds3, Jeffrey Edberg3, Pariyaphon Lertprachakwong3, Hannah Darroch4, Megan Leask4, Mumin Ozturk5, Brenda Kischkel5, Nicholas Sumpter5, Leo Joosten5 and Nils Asmann5, 1University of Alabama at Birmingham, Homewood, AL, 2University of Aucklabd, Auckland, New Zealand, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Otago, Dunedin, New Zealand, 5Radboud University Medical College, Nijmegen, Netherlands

    Background/Purpose: CSF1 and CSF1R encode a secreted and membrane-bound cytokine and its receptor controlling differentiation of monocytes into macrophages and inflammatory activity of macrophages. There…
  • Abstract Number: 1539 • ACR Convergence 2025

    The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis

    Muhammad Usman Hashmi1, Paramarajan Piranavan2, Yasmeen Sufi3, Zaira Nasir4, Zainab Azhar5, Shamaem Tariq5, Hamas Ul Hudaibia5, IMRAN SAEED6, Aayet Zulfiqar5, Natasha Rasool2 and Anum Faiz7, 1Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, 2University of Kentucky, Louisville, KY, 3Karachi Medical & Dental College, Karachi, Karachi, Pakistan, 4Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, 5Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, 6Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, 7Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan

    Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
  • Abstract Number: 0903 • ACR Convergence 2025

    Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling

    Catherine Wioland1, Corinne Vedrine2, Caroline Walter1, Fanny Marque2, Thomas Dannequin2, Melanie Cecci1, David Buffet1, Cindy Schmid1, Elena Degl'Innocenti1, Gautier Robert1, Grazyna Wieczorek1, David Schubert1, Catriona Paape1 and Isabelle Isnardi3, 1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, 3Novartis, Gueberschwihr, France

    Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…
  • 1
  • 2
  • 3
  • …
  • 42
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology